KIR/HLA interactions negatively affect rituximab-but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 5618-5624

  Terszowski, Grzegorz ^a   Klein, Christian ^b   Stern, Martin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Roche Glycart AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; OBINUTUZUMAB; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TARGET CELL;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; FEMALE; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MUTATION, MISSENSE; RECEPTORS, IGG; RECEPTORS, KIR;

EID: 84902178747     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400288     Document Type: Article

References (27)

1. Stern, M., and R. Herrmann. 2005. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 54:11-29.
2. Maloney, D. G. 2012. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366:2008-2016.
3. Griffin, M. M., and N. Morley. 2013. Rituximab in the treatment of non-Hodgkin's lymphoma: a critical evaluation of randomized controlled trials. Expert Opin. Biol. Ther. 13:803-811.
4. Cang, S., N. Mukhi, K. Wang, and D. Liu. 2012. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 5:64.
5. Mössner, E., P. Brünker, S. Moser, U. Püntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, A. Nopora, E. Van Puijenbroek, et al. 2010. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-4402.
6. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99:754-758.
7. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947.
8. Mellor, J. D., M. P. Brown, H. R. Irving, J. R. Zalcberg, and A. Dobrovic. 2013. A critical review of the role of Fcγ receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 6:1.
9. Ghesquières, H., G. Cartron, J. F. Seymour, M. H. Delfau-Larue, F. Offner, P. Soubeyran, A. Perrot, P. Brice, R. Bouabdallah, A. Sonet, et al. 2012. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120:2650-2657.
10. Pennell, N. M., T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein. 2008. Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma. Haematologica 93:1265-1267.
11. Nagler, A., L. L. Lanier, S. Cwirla, and J. H. Phillips. 1989. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 143:3183-3191.
12. Moretta, L., and A. Moretta. 2004. Killer immunoglobulin-like receptors. Curr. Opin. Immunol. 16:626-633.
13. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331-342.
14. Machino, T., Y. Okoshi, Y. Miyake, Y. Akatsuka, and S. Chiba. 2012. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells. Immunol. Invest. 41:831-846.
15. Binyamin, L., R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner. 2008. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J. Immunol. 180:6392-6401.
16. Frohn, C., P. Schlenke, B. Ebel, C. Dannenberg, G. Bein, and H. Kirchner. 1998. DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J. Immunol. Methods 218:155-160.
17. Koehler, R. N., A. M. Walsh, N. Moqueet, J. R. Currier, M. A. Eller, L. A. Eller, F. Wabwire-Mangen, N. L. Michael, M. L. Robb, F. E. McCutchan, and G. H. Kijak. 2009. High-throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real-time PCR. Tissue Antigens 74:73-80.
18. Dall'Ozzo, S., C. Andres, P. Bardos, H. Watier, and G. Thibault. 2003. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in realtime multiplex allele-specific PCR. J. Immunol. Methods 277:185-192.
19. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294:15-22.
20. Witzig, T. E., C. Y. Li, A. Tefferi, and J. A. Katzmann. 1994. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol. 101:312-317.
21. Pende, D., G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al. 2005. Analysis of the receptorligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105:2066-2073.
22. Parsons, M. S., K. Zipperlen, M. Gallant, and M. Grant. 2010. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. J. Leukoc. Biol. 88:905-912.
23. Kohrt, H. E., A. Thielens, A. Marabelle, I. Sagiv-Barfi, C. Sola, F. Chanuc, N. Fuseri, C. Bonnafous, D. Czerwinski, A. Rajapaksa, et al. 2014. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-686.
24. Herter, S., F. Herting, O. Mundigl, I. Waldhauer, T. Weinzierl, T. Fauti, G. Muth, D. Ziegler-Landesberger, E. Van Puijenbroek, S. Lang, et al. 2013. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12:2031-2042.
25. Tarek, N., J. B. Le Luduec, M. M. Gallagher, J. Zheng, J. M. Venstrom, E. Chamberlain, S. Modak, G. Heller, B. Dupont, N. K. Cheung, and K. C. Hsu. 2012. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122:3260-3270.
26. Delgado, D. C., J. A. Hank, J. Kolesar, D. Lorentzen, J. Gan, S. Seo, K. Kim, S. Shusterman, S. D. Gillies, R. A. Reisfeld, et al. 2010. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 70:9554-9561.
27. Goede, V., K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C. M. Wendtner, T. Chagorova, J. De La Serna, M. S. Dilhuydy, T. Illmer, et al. 2014. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370:1101-1110